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Post-transplantation nephrosis in congenital nephrotic syndrome of the
Finnish type. Congenital nephrotic syndrome of the Finnish type (CNF)
is an autosomal recessively inherited disease manifesting as massive
proteinuria, edema and ascites in the neonatal period. The disease is
believed to be limited to the kidneys and recurrences after renal
transplantation have not been reported. At our center 29 transplanta-
tions have been performed on 28 CNF patients. One to 33 months after
transplantation, seven grafts (24%) of six patients have developed a
steroid-resistant nephrotic syndrome. The clinical data and renal his-
tology of these patients were analyzed in order to elucidate the cause of
the proteinuria. At the onset of six of the seven episodes of nephrosis,
the patient had evidence of a preceding CMV- or EBV-infection and the
remaining patient had sinusitis. Upon light and electron microscopy
examination, endothelial swelling of the glomerular capillaries resem-
bling transplant glomerulopathy (TG) was seen, but unlike TG, the
glomerular basement membranes were normal. The response of pro-
teinuna to steroid or cyclophosphamide therapy was poor, with total
remission in only two patients and partial remission in one patient, all
treated with methylprednisolone and cyclophosphamide immediately
after the diagnosis. Four grafts have been lost. Our data show that CNF
patients have an increased tendency for post-transplantation nephrosis.
Congenital nephrotic syndrome of the Finnish type (CNF) is
a hereditary disease occurring sporadically around the world. In
Finland it is common with an incidence of 12 per 100,000 live
births [1]. The disease manifests itself with massive proteinuria
leading to edema and ascites during the first months of life.
Without treatment most patients die in early infancy. Today the
treatment consists of aggressive protein supplementation, bilat-
eral nephrectomy, and a subsequent renal transplantation (1—4).
Until recently both one year patient and graft survivals were
100% at our center [5]. Currently, it is believed that the disease
is limited to the kidneys, and there is no recurrence after
transplantation.
Post-transplantation proteinuna has been reported in three
patients with CNF [6—8]. In two of these the proteinuria
responded to steroid treatment [6, 7] and in one to steroid and
cyclophosphamide [8]. At our center 29 renal transplantations
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have been performed on 28 CNF-patients between the years
1987 and 1992. Seven grafts (24%) transplanted to six patients
have subsequently developed massive steroid-resistant protein-
uria. The clinical and histological data of these patients were
analyzed in order to discern the cause of nephrosis.
Methods
Clinical background
CNF was diagnosed soon after birth on clinical grounds
excluding other causes of congenital nephrosis [9]. At nephrec-
tomy the diagnosis was histologically [10] confirmed in all
patients. Detailed pretranspiant treatment of CNF patients has
been previously described [2—4].
ABO-compatibility and a negative T cell crossmatch were
prerequisites for transplantation. Graft matching aimed at ac-
cepting only grafts with a maximum of three mismatches with a
maximum of one in each H LA-A, -B and -DR loci. HLA-typing
was performed using a standard two-stage microcytotoxicity
assay [11].
Renal transplantation was performed at the age of 1.2 to 7.3
years. Pre-transplantation data and early complications are
presented in Table 1. Additionally, patient 6 developed a
lymphocele and necrosis of the ureter which, after an initial
pyelostoma, was neoimplanted twice. The final implantation
was performed 14 months after the transplantation.
Growth hormone therapy for poor growth was initiated in
patients 2 and 6, 16 and 18 months after transplantation,
respectively. In patient 2 the treatment was discontinued at the
onset of the first nephrotic episode (2a).
Immunosuppression
Cyclosporine (CsA) was started preoperatively with an indi-
vidual pharmacokinetically determined dose aiming at a trough
blood concentration of 300 sg/liter (specific monoclonal radio-
immunoassay, Sandimmun Kit®, Sandoz, Basel, Switzerland)
at transplantation [12]. Methylprednisolone (MP, 100 mg i.v. in
three doses) and azathioprine (1.4 mg/kg i.v. in two doses) were
given intraoperatively.
Post-operative immunosuppression included: (1) methylpred-
nisolone 1 mg/kg/day, which was tapered down to 0.25 mg/kg!
day at three weeks and 0.37 mg/kg (a 25% reduction of the daily
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Table 1. Characteristics and complications of CNF patients who developed post-transplantation nephrotic syndrome
Patient I 2a 2b 3 4 5 6
Sex F M M M M M M
Age at Tx years 1.2 3.5 7.3 1.3 2.3 2.7 1.8
Donor CAD CAD CAD LRD CAD CAD LRD
HLA mismatch-AB/-DR 2/1 2/1 1/1 1/1 2/1 2/1 2/1
CMV status (recipient/donor) +1— —1+ +1+ +1+ —1+ —1+ —1+
Recipient EBV status — — — ND — + —
Early complications (4 to 9
weeks) after Tx
Acute rejection episodes N 3 3 b 1 iC 0 2
Treated CMV infections N 0 0 0 0 1 1 0
Septic infections N 0 Peritonitis
Pneumonia
0 0 Pyelonephritis 0 Pyelonephritis
Late complications before
the onset of nephrosis
Treated CMV infections N 0 0 0 0 0 0 0
Septic infections N Pneumonia 0 0 0 0 0 0
Abbreviations are: 2a, patient 2—first transplantation; 2b, patient 2—second transplantation; M, male; F, female; Tx, transplantation; CAD,
cadaver donor; LRD, living related donor; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ND, not done.
a Twins.b Acute vascular rejection—treated with steroid, cyclophosphamide, ATG and plasmapheresis.
C Steroid resistant—treated with ATG.
dose) every other day after three months; (2) azathioprine
2 mg/kg/day, which was reduced to 1 mg/kg/day after two weeks
and increased to 1.4 mg/kg/day after three months when MP
was reduced; and (3) CsA, which was kept at a trough blood
concentration of 300 j.g/liter immediately after transplantation
and between 50 and 100 pjg/liter after six months. CsA was
given in three daily doses [13].
All patients except patient 2 after his second transplantation
(patient 2b) were on standard triple immunosuppressive ther-
apy. He developed an early acute vascular rejection and re-
ceived cyclophosphamide instead of azathioprine for the first
five months. After that his immunosuppression was similar to
that of the other patients.
Infections: Diagnosis and treat,nent
Anti-cytomegalovirus (CMV) immunoglobulin (Cytotect®,
Biotest Pharma, Dreieich, Germany) was given intravenously
every two to four weeks for three months to all patients with a
CMV-positive donor. The diagnosis of CMV infection was
based on the detection of CMV-specific antigens (pp65) [14, 15]
in blood leukocytes or the graft, and shell vial cultures from
blood, urine and biopsy material [16]. The patients with CMV-
viremia and/or a CM V-positive finding in the graft were treated
with intravenous gancyclovir (Cymevene®, Syntex Nordica,
SOdertälje, Sweden) for at least two weeks. Trimetoprim-
sulfamethoxazole prophylaxis for Pneumocystis carinii was
given for one year [171.
1gM and IgG antibodies against Epstein-Barr virus (EBV)
viral capsid antigens were analyzed by indirect immunofluores-
cence tests (EBV IgG and 1gM test kits, Gull Laboratories, Salt
Lake City, Utah, USA). CMV specific IgG and 1gM were
determined by ELISA (Labsystems, Helsinki, Finland). Serum
antibodies against adeno-, influenza type A-, influenza type B-,
parainfluenza- 1, parainfluenza-3, respiratory syncytial-, paroti-
tis-, rubella-, rota-, entero-, herpes simplex I-, varicella zoster-
and cytomegaloviruses, Mycoplasma pneumoniae, Chlamydia
trachomatis and Toxoplasma gondii were analyzed by comple-
ment fixation technique (CF-screen).
Rejections: Diagnosis and treatment
Fine-needle aspiration biopsies (FNAB) [18] were routinely
taken on the fifth day after transplantation and at least twice a
week until the patient was discharged from the hospital. An
FNAB was also taken if an acute rejection was suspected on
clinical grounds. Acute rejection was defined as fever, an
increase in serum creatinine concentration and a total corrected
increment (TCI) of 3.0 and a blast cell increment of at least 1%
in an FNAB. Acute rejections were treated with 1.5 mg/kg
methyiprednisolone per os followed by 3 mg/kg/day of methyl-
prednisolone divided into four doses per as for five days or until
the blast cell reaction in FNAB subsided. If no response was
seen in five days a renal core biopsy was performed and
anti-thymocyte globulin (ATG®, Fresenius, Porgenberg, Ger-
many; 3 mg/kg/day) used if the acute rejection persisted.
Histology
A renal core needle biopsy was taken within three days from
the onset of nephrosis in all patients (exception: patient 2a on
day 14). A total of 13 control biopsies were performed on
patients 1, 2a, 3 and 6 during proteinuria. For routine light
microscopy the biopsies were stained with hematoxylin-eosin,
periodic acid Schiff (PAS), Masson's trichrome and methena-
mine silver PAS methods. All biopsies were analyzed by two
investigators (JL and LK). Histological changes were semi-
quantitatively scored using a method previously described [19].
Electron microscopy was performed by a single investigator
(JR).
Standard immunohistology was performed using monoclonal
antibodies against Clq, C3, IgA, IgG, 1gM and fibrin. In
addition, the presence of IL-i, TNF-a and TGF-f3 in kidneys
during proteinuria was immunohistochemically analyzed [20].
The presence of T-lymphocytes and activated lymphoid cells
Lame et a!: Post-Tx nephrosis in CNF patients 869
Table 2. Infectious findings at the onset of nephrosis in CNF patients who developed post-transplantation nephrotic syndrome
Patient 1 2a 2b 3 4 5 6
Time after Tx months 18 28 14 7 5 1 33
Clinical signs of infection Mild upper
respiratory
tract
infection
Conjunctivitis
Chronic
maxillary
sinusitis
Chronic
maxillary
sinusitis
None None None Mild upper
respiratory
tract
infection
CMV-positive blood or — — — a
graft culture
Urinary CM V-excretion
Elevated s-EBV IgMIIgG
—
+/+b
ND
ND
+/b +ND ++1+" ++1+ —+1_c
CF-screen — — — —
Abbreviations are: 2a, patient 2—first transplantation; 2b, patient 2—second transplantation: Tx, transplantation; CMV, cytomegalovirus; EBV,
Epstein-Barr virus; ND, not done; CF-screen, broad screening of antibodies against infectious organisms by complement fixation tests.
a Anti-CMV IgG titer 6400.
b Anti-EBV IgG antibodies developed after transplantation.c +1+ when controlled 4 weeks later.
was examined from frozen sections stained by a three layer
indirect immunoperoxidase technique using monoclonal anti-
bodies against CD2 or CD3 and IL-2 receptor. HLA-class II
expression was analyzed using a similar technique [211. The
presence of anti-glomerular basement membrane (GBM) and
other auto-antibodies in the patients' sera at the onset of
proteinuna was analyzed by routine immunofluorescence meth-
ods [20]. A Mann-Whitney U-test was used for statistical
analysis.
Results
Clinical findings
Seven of the 29 grafts (24%) transplanted to CNF patients at
our institution developed a post-transplantation nephrosis in
contrast to none of 32 grafts transplanted to patients with other
diseases (P < 0.01). There were no significant differences in
male/female ratio, age at transplantation, donor source, recipi-
ent or donor CMV status prior to transplantation, acute rejec-
tion episodes or septic infections between the transplantations
leading to nephrosis and the other 22 transplantations on CNF
patients at our institution (Table 1). All nephrotic grafts had one
DR-mismatch in contrast to a mean number of 0.50 HLA-DR
mismatches in other CNF-patients' grafts (P =0.02). There was
no significant difference in the number of HLA-A and -B
mismatches between the groups. Four of the six treated CMV-
infections that have occuried in CNF-patients after transplan-
tation took place in the nephrotic patients.
The mean interval between transplantation and the onset of
nephrosis was 15 months (range 1 to 33 months) (Table 2). All
except patients 1 and 2b had normal renal function prior to the
onset of nephrosis. Patient 1 had slight hematuria and patient 2b
slightly increased urinary protein excretion (1 g/liter) which had
continued since the early acute vascular rejection.
At the onset of nephrosis three patients did not have any
clinical signs of infection. However, including those three
patients, six of the seven patients demonstrated positive labo-
ratory findings of either active or recent CMV or EBV infec-
tion. The remaining patient was not investigated for EBV-
serology or urine CMV but had an acute exacerbation of his
chronic sinuitis. CMV was found in four patients. In two
patients CMV viremia or positive CM V-antigen detection in the
renal tubuli occurred together with urinary excretion. In two
patients CMV was only cultured from urine—in one accompa-
nied by a very high serum CMV-IgG titer. Positive EBV-IgM/
IgG serology indicated an active or recent infection in five of
seven patients, three of them also having findings positive for
CMV. No evidence of other infections was demonstrated by
CF-antibody screen. Leukocytosis was not present in any
patient. Differential white blood cell count was normal in all
patients except patients 3 and 5 who had lymphocytosis (59 and
71%, respectively).
Blood cyclosporine concentration was within the target limits
in all patients except in patients 1 and 5 whose values exceeded
the target levels by 160% and 70%, respectively (Table 3).
Serum creatinine concentration had increased by more than 20
tmoI/liter since the previous control in all patients except in
patients 2b and 4. Their creatinine concentrations had de-
creased from 87 to 70 and from 69 to 59 smol/liter, respectively.
Serum albumin and protein concentrations were abnormally
low and the patients had massive proteinuria. Hematuria was
seen in all patients except in patient 4. Anti-GBM antibodies
were not detected (patients 1 through 3 investigated).
All patients were treated with steroids—six in combination
with cyclophosphamide (Table 4). Complete remission was
achieved in three patients—in all within 12 days from the onset
of nephrosis. Subsequent relapse occurred in two of them with
a new remission achieved in one patient. Currently patients 2b
and 4 are in remission. In the others proteinuria did not respond
to therapy although alleviation was achieved in two patients.
One of these (patient 6) currently has mild proteinuria (1 g124
hr). Of the four patients in whom CP was initiated immediately
after the diagnosis two are in remission and one is proteinuric.
The response of the remaining patient was not clear as he
developed anuria on day four. CP did not induce remission in
the patients in whom it was instituted later.
During the follow-up proteinuria tended to increase with time
and albumin substitutions were necessary in six patients. The
mean of highest recorded daily urine protein excretions was 23
g/24 hr (range 8 to 42, not done in patient 5). Hematuria usually
accompanied proteinuria. The renal function of patients 1, 2a
and 3 deteriorated rapidly necessitating dialysis after a mean of
eight months (range 2 to 15 months) and transplantectomy after
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Table 3. Characteristics of patients with CNF at the onset of nephrotic syndrome and at last control
Patient 1 2a 2b 3 4 5 6
At the onset of nephrosis
Time from Tx months 18 28 14 7 5 1 33
B-CsA pg/1iter 260 60 200 70 160 520 70
Sçr .tmo1/1iter 151 85 70 92 59 105 178
Saib glliter 17 25 23 17 21 23 18
Uprot glliter 3 43 6 17 46 59 3
UerPerfield 15 >200 >200 187 0 115 147
FNAB AR Normal Normal Normal Normal AR Normal
Core needle biopsy AR/ES ES ES ES ES ARIES ES
At last control
Time from onset of
nephrosis months 13 6 3 17 11 1.5 6
5Cr j.unollliter 598 582 75 595 65 425 81
Saib glliter 21 21 35 28 37 ND 12
Uprot g/liter
Uerperfield
36
95
88
>200
0.1
1
30
l5 0,17 35ND 1.00
Core needle biopsy End-stage End-stage ES End-stage ND ND ES
Abbreviations are: 2a, patient 2—first transplantation; 2b, patient 2—second transplantation: B-CsA, blood cyclosporine concentration; Sr,
serum creatinine concentration; Sprot, serum protein concentration; urine protein concentration; Uer, urine erythrocytes; Saib, serum albumin
concentration; FNAB, fine needle aspiration biopsy; ND, not done; AR, acute rejection; ES, endothelial swelling.
a Before nephrectomy.
Table 4. Therapy and response to therapy of post-transplantation nephrotic syndrome at last control in patients with CNF
Outcome
Patient Anti-proteinuric therapya Start of CP therapy Other therapy Response of proteinuria (time from onset)
I MP 3 and CP 2 mg/kg/day Five months from the
onset of nephrosis.
Albumin replacement Initial remission with MP on
day 9. Relapse on day 32. No
response to MP or CP.
Tx-ectomy
(13 months)
2a MP 1.8 mg/kg/day None Albumin replacement No response. Tx-ectomy
(3 months)
2b MP 2 and CP 3.2 mg/kg/day On diagnosis Albumin replacement Remission on day 7 Remission
(6 weeks)
3 MP 3 and CF 2 mg/kg/day 12 months from the
onset of nephrosis.
IV gancyclovir 2 weeks
Albumin replacement
Initial decrease on MP.
Reincrease. No response to
MP or CP.
Tx-ectomy
(17 months)
4 MP 3 and CP 2.5 mg/kg/day On diagnosis Oral acyclovir 2 weeks
Albumin replacement
Remission on day 12. Relapse
on day 110. after decrease of
MP and CP. Remission on
day 120.
Remission
(11 months)
5 MP 2.3 and CP 0.8 mg/kg/day On diagnosis I.V. gancyclovir 2 weeks Uncertain. Anuria on day 4 and
a fatal hypertensive crisis on
day 57.
Exitus (day 57)
6 MP 1.7 and CP 3.5 mg/kg/day On diagnosis Oral acyclovir 2 weeks
Albumin replacement
Decrease to 1 g/24 hr. Slight proteinuria
(6 months)
Abbreviations are: CP, cyclophosphamide; MP, methylprednisolone; 2a, patient 2—first transplantation; 2b, patient 2—second transplantation.
Azathioprine was stopped in every patient. Low dose CsA was continued except in patient 2a.
a mean of 12 months (range 6 to 17 months). Patient 5 died due
to a hypertensive crisis 57 days after the onset of nephrosis.
Histological findings
The most prominent glomerular change in initial core needle
biopsies was swelling of capillary endothelial cells with en-
larged hyperchromatic nuclei (Table 5). The swelling was
marked in patients 1, 2a and 3 and occurred less prominently in
all other patients. Only part of the glomeruli were affected (Fig.
1). Mesangial cell proliferation was present in all biopsies.
Mesangial matrix increase, varying vascular changes, diffuse
interstitial fibrosis, lymphocyte inflammation, tubular dilation
and tubular atrophy were seen in most biopsies. Fine-needle
aspiration biopsies were normal in all patients except in patients
1 and 5 in whom acute rejection was seen and verified by core
needle biopsy (Table 3). After steroid treatment FNABs were
normal also in these patients.
Electron microscopy (EM) of the initial biopsies in patients 1,
2a, 2b, 3 and 6 verified the finding of endothelial swelling and
mesangial cell and matrix proliferation. In addition, podocyte
foot process effacement was seen. The glomerular basement
membranes were normal and no deposits were observed. Elec-
tron lucent zone under lamina rara interna could not be seen
(Fig. 2).
Routine immunofluorescence of biopsies of patients I
through 3 was normal. Patient 2a had small fibrin deposits in
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Table 5. Glomerular, vascular and other light microscopy findings in core needle biopsies taken at the onset of proteinuria
Patient I 2a 2b 3 4 5 6 Mean
Glomeruli
Mesangial cell proliferation 2 1 1 2 1 1 2 1.4
Endothelial swelling 2 2 1 2 1 1 1 1.4
Mesangial matrix increase 1 0 1 1 1 1 2 1.0
Capillary BM thickening 1 0 0 0 0 0 0 0.1
Capillary BM duplication 0 1 0 0 0 0 0 0.1
Bowman capsular thickening 1 1 1 0 0 1 1 0.7
Inflammation
lymphocytes 1 0 0 0 0 1 1 0.4
neutrophils 0 0 0 0 0 1 0 0.1
Arteries
Endothelial swelling 0 0 0 2 0 0 0 0.3
Endothelial proliferation 1 0 0 0 0 1 0 0.3
Intimal proliferation 2 0 0 1 0 1 0 0.6
Inflammationa 1 0 0 0 0 1 1 0.4
Arterioles
Endothelial swelling 0 0 1 2 0 0 0 0.4
Endothelial proliferation 2 1 0 1 0 1 0 0.7
Intimal proliferation 2 0 0 1 0 1 1 0.7
Infiammationa 1 0 0 0 0 1 0 0.3
Obliteration 1 0 0 0 0 0 0 0.1
Other
Tubular inflammationa 1 0 0 1 0 I 0 0.4
Tubular dilatation 2 1 1 1 0 0 1 0.9
Tubular atrophy 2 1 0 1 1 0 2 1.0
Diffuse interstitial fibrosis 1 2 0 1 0 1 2 1.0
—
Diffuse interstitial inflammationa 1 1 0 1 0 1 1 0.7
Findings are rated from 0 to 3 with increasing intensity. 2a, patient 2—first transplantation; 2b, patient 2—second transplantation.
a Lymphocytes.
glomerular and interstitial capillaries. Patient 3 had insignificant
amounts of 1gM in the glomerular mesangium and some fibrin in
the interstitium.
Increased tubular HLA-class II expression was seen in all
patients except patient 2b at the onset of nephrosis (the biopsy
of patient 3 excluded due to tissue destruction). An increased
number of CD2 positive cells were seen in tubuli of the two
patients with acute rejection and in the interstitium of one of
them. Staining for IL-2 receptor was negative in all biopsies.
Slightly increased IL-i and TGF-/3 and slightly decreased
TNF-a expression was seen in glomerular mesangial matrix in
biopsies of patients 1, 3, 5 and 6 taken during proteinuria.
Control core needle biopsies taken in patients 1, 2a, 3 and 6
during continuing proteinuria showed that the predominant
glomerular findings of endothelial swelling and proliferation of
mesangial cells became less marked with time and were gradu-
ally replaced by mesangial matrix proliferation as the most
prominent glomerular change. Capillary basement membrane
thickening was uniformly seen but duplication observed only in
patient 2a. Despite diminishing inflammation vascular changes
progressed and interstitial fibrosis increased. Transplantecto-
mized grafts showed extensive interstitial fibrosis, glomerular
sclerosis, tubular dilation and epithelial atrophy, as well as
arteriolar and arterial intimal proliferation.
Discussion
Twenty-nine transplantations have been performed on CNF-
patients at our institution in the years 1987 to 1992. The
prognosis of these patients has generally been excellent. During
the last three years seven grafts (24%) have suddenly developed
a nephrotic syndrome with a poor response to either steroid or
cyclophosphamide treatment. The nephrosis seems to be a
particular problem of CNF patients as no patient transplanted
for other diseases has developed it. In view of the future
transplantation policy it is imperative to know why a high
percentage of CNF patients present with post-transplantation
proteinuria.
Heavy proteinuria is reported to occur in 8 to 11% of renal
allografts in adults [22—241. It has been attributed to recurrence
of the original disease, de novo glomerulonephritis, chronic
rejection and transplant glomerulopathy [22—27].
Possible recurrence of CNF is difficult to establish. Histolog-
ically CNF kidneys present with mainly non-specific changes.
Characteristic features are tubular dilation and atrophy, mesan-
gial hypercellularity and matrix increase as well as dilation of
Bowman's space in light microscopy. In electron microscopy
spreading of podocyte foot processes, irregular thickening of
the lamina rara interna and thin GBM lamina densa can be seen.
Routine immunofluorescence is usually negative [10]. Although
mesangial hypercellularity and matrix increase were regularly
seen in the biopsies, tubular dilation and atrophy were minimal
and wide urinary spaces were not present. In addition, endo-
thelial swelling seen in all initial biopsies has not been reported
in CNF. The podocyte foot process effacement observed in EM
may be a secondary non-specific change due to heavy protein-
uria. On the other hand, the lamina densa of the glomerular
basement membranes were of normal thickness. Clinically, the
response of nephrosis to CP-therapy in three patients and the
rapid deterioration of renal function in others do not fit CNF. It
therefore seems unlikely that the nephrotic syndrome repre-
sents recurrence of CNF.
The most common de novo glomerulopathies occurring in
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Fig. 1. Endothelial swelling in an affected glotnerulus (Toluidine stain, original magnification I000X).
renal grafts are membranous glomerulopathy, anti-GBM anti-
body nephntis and possibly focal segmental glomeruloscierosis
[28]. In our patients immunofluorescence and EM-findings of
the nephrotic kidneys were negative and anti-GBM antibodies
not detected in serum excluding the possibility of de novo
glomerulopathy. However, in patients 4 and 5 neither immuno-
fluorescence nor EM were performed.
Sporadic cases of post-transplantation proteinuria with a
histological picture similar to minimal change nephrotic syn-
drome (MCNS) have been reported [6—8, 29]. Among them are
all previous CNF patients with post-transplantation nephrosis.
In our patients the endothelial and mesangial cell swelling do
not fit the definition of MCNS. However, all glomeruli did not
show the swelling and the normal appearance of many of them
could lead to a diagnosis of MCNS.
Endothelial cell swelling limited to the glornerular capillaries
has not been reported as an independent feature leading to graft
loss. However, endothelial cell swelling of other capillaries,
arterioles and arteries may occur during acute vascular rejec-
tion or during rejections with both vascular and cellular com-
ponents [30—32]. In these instances the swelling is consecutively
accompanied by the other diagnostic findings of intimal prolif-
eration, vascular wall inflammation, interstitial hemorrhage and
patchy infarction combined with focal inflammatory infiltration
of tubuli and/or glomeruli. Endothelial cell swelling may also
occur in chronic rejection, although the histological findings are
dominated by chronic inflammatory reactions involving vessels,
interstitium and glomeruli [18]. In our patients the histological
findings did not correspond with those of acute vascular rejec-
tion. Also, although interstitial fibrosis, tubular atrophy and
vascular lesions indicative of chronic rejection were seen in
four patients at the onset of nephrotic syndrome, the changes
were slight and not significantly different from those seen in
other CNF patients' biopsies taken 12 to 24 months after
transplantation. These changes alone do not explain the mas-
sive proteinuria.
Transplant glomerulopathy may occur at any time after
transplantation and usually manifests itself by an increased
serum creatinine concentration often combined with protein-
uria. Typical histological findings may also be observed in a
well-functioning graft [33]. The earliest change in transplant
glomerulopathy is swelling of endothelial and mesangial cells of
glomeruli with increase in cell number. With time an increase in
mesangial matrix with a spongy outlook and basement mem-
brane thickening and reduplication is seen. In electron micros-
copy double contours in GBM separated by electron lucent
zone under lamina rara interna and diffuse effacement of
podocyte foot processes have been reported. These changes are
always associated with vascular lesions of varying degree.
Granular mesangial 1gM is often seen diffusely in immunofluo-
rescence [27]. Proteinuria can be profuse in transplant glomer-
ulopathy with a peak protein loss of 23 g/24 hr reported 123].
Usually it is less severe [23, 27, 29]. The glomerulopathy may
rapidly lead to graft loss. In the report of Maryniak et a!, 77% of
grafts were lost, 91% of these within the first year [27]. A
somewhat better prognosis has been reported by Vathsala et a!
who found that 50% of the patients lost their grafts (median time
to graft loss 13.4 months) [23]. In our patients, proteinuria, the
variable time of its onset, the rapid progression to renal failure
in some cases, and the primary histological finding of swelling
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Fig. 2. Endothelial swelling, absence of subendothelial electron lucent
glomerulus (electron microscope, original magnification 2500x).
of glomerular endothelial and mesangial cells accompanied by
vascular changes correspond to transplant glomerulopathy.
However, the incidence of nephrotic syndrome and rate of
urine protein loss were higher in our patients than previously
reported; the incidence of transplant glomerulopathy in the
study of Maryniak was 4.3% [27]. Also, in our patients the
endothelial swelling tended to decrease with time in contrast to
reports of similar swelling at transplantectomy [271. Moreover,
we did not find the electron lucent zone under the lamina rara
interna in EM, although it might have been observed in later
biopsies had EM material been available.
A glomerular lesion similar to transplant glomerulopathy has
been attributed to CMV-infection [33]. Subsequently, it has
been shown that CM V-infection is not a prerequisite for trans-
plant glomerulopathy, but a possible triggering effect of the
virus in some of the cases cannot be excluded [34, 35]. In the
present study more episodes of CMV-disease occurred in
nephrotic than other CNF patients, and in two patients CMV
was cultured from the graft or blood at the onset of nephrosis.
In four other patients elevated anti-EBV 1gM was seen, with
one of them developing IgG antibodies within four weeks. The
exact timing of EBV-infections is, however, difficult to judge
since serological findings can persist for months in immunosup-
pressed patients. Infectious parameters have not been reported
in the other CNF patients with post-transplantation proteinuria,
but relapses were accompanied by respiratory infections in one
patient [7]. The role of infection in the development of nephro-
sis is supported by the increased tubular HLA-class II expres-
sion in most biopsies. Similar expression has been reported to
zone and slight accumulation of mesangial matrix in an affected
occur in CMV and other infections [36, 37]. Acute rejection also
induces tubular HLA-class II expression but on a higher scale
than seen in our patients without concurrent acute rejection
[38].
We have tried two therapies for the nephrosis: methylpred-
nisolone alone or combined with cyclophosphamide. Only two
patients are in remission and one has mild proteinuria. They
were treated with combination therapy and the treatment was
started immediately after the diagnosis. A transient remission
was achieved with MP in one patient, but combination therapy
started after subsequent relapse did not have any effect. Pa-
tients in whom the therapy has been delayed have responded
poorly. Although two steroid-dependent patients have been
reported [5, 6], the best course of action seems to be aggressive
treatment with cyclophosphamide and methyiprednisolone im-
mediately from the onset of symptoms. However, even with
such therapy remission may not be reached.
In conclusion, post-transplantation nephrosis in CNF pa-
tients is associated with histological features resembling to
some extent those of transplant glomerulopathy. It seems to be
preceded by infection caused by CMV, EBV or perhaps other
viruses. Recurrence of CNF cannot be definitely excluded but
seems unlikely. Without aggressive therapy prognosis is poor.
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